ArticleThe journal of prevention of Alzheimer's disease2025

Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease.

Sarah Abbas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.